Ventrus Biosciences, Inc. Completes Enrollment of Pivotal Phase 3 Trial of Diltiazem (VEN 307) in Patients With Anal Fissures

NEW YORK, Dec. 21, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced that S.L.A. Pharma has completed patient enrollment and randomization in the first Phase 3 clinical trial of Diltiazem (VEN 307) in patients with anal fissures. Initial top-line data from the Phase 3 study is expected to be available in May 2012. Ventrus Biosciences has licensed the North American rights to diltiazem hydrochloride cream from S.L.A. Pharma.